p53 Codon 72 Increased Biochemical Recurrence Risk after Radical Prostatectomy in a Southern Chinese PopulationXu B.a, b · Mi Y.-Y.a · Min Z.-C.a · Cheng G.a · Tong N.b · Tao J.a · Li P.-C.a · Wang M.-L.b · Tang J.-L.b · Zhang Z.-D.b · Song N.-H.a · Zhang W.a · Wu H.-F.a · Feng N.-H.a · Hua L.-X.a
aDepartment of Urology, First Affiliated Hospital of Nanjing Medical University, and bDepartment of Molecular and Genetic Toxicology, Cancer Center of Nanjing Medical University, Nanjing, China
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Introduction: Alterations in P53 and Murine Double Minute 2 (MDM2) genes appear to be important in the development of many human tumors. We investigated the potential prognostic roles of p53 codon 72 and MDM2 309 and 1797 polymorphisms in prostate cancer after radical prostatectomy. Patients and Methods: Fifty southern Chinese with prostate cancer undergoing radical prostatectomy were included in this study. All polymorphisms were detected by PCR-RFLP. Their prognosis on biochemical recurrence was assessed using Kaplan-Meier analysis and Cox regression model. Results:p53 codon 72 GG genotype was associated with increased biochemical recurrence compared with CG+CC genotypes and poorer PSA-free survival. It was also noted that GG genotype was an independent risk factor for biochemical recurrence after radical prostatectomy on multivariate analysis. No statistical difference was observed in MDM2 polymorphisms and prostate cancer prognosis. Conclusion: Our data revealed that p53 codon 72 GG genotype carriers more frequently show biochemical recurrence than CG+CC genotypes carriers.
© 2010 S. Karger AG, Basel
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
- Gu F: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in china. Chin Med J (Engl) 2000;113:299–302.
- Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555–565.
- Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–439.
- Hallstrom TM, Laiho M: Genetic changes and DNA damage responses in the prostate. Prostate 2008;68:902–918.
- Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857–860.
- Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8: 162–200.
- Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125–128.
- Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, et al: Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007;13:6632–6638.
- Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, et al: Bcl2 -938c/a polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009;181:1907–1912.
- Bond GL, Hu W, Levine A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481–5484.
- Wang M, Zhang Z, Zhu H, Fu G, Wang S, Wu D, et al: A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a chinese population. Clin Cancer Res 2008;14:3633–3640.
- Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al.: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434–4440.
Jaboin JJ, Hwang M, Perez CA, Cooper C, Chen H, Ye C, et al: No evidence for association of the MDM2–309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol DOI: 10.1016/j.urolonc.2009.03. 031.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.